Sar studies on mglu5 receptor positive allosteric modulators (2003-2013)

Current Topics in Medicinal Chemistry

Volumn 14, Issue 15, 2014, Pages 1789-1841

  Hao, Junliang ^a   Xiong, Hui ^b  

^a ELI LILLY AND COMPANY   (United States)

^b AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

GPCR; MGlu5 receptor; Positive allosteric modulators (PAM); SAR; Schizophrenia

Indexed keywords

AMPHETAMINE; ARYLETHYNYLPYRIMIDINE DERIVATIVE; AZETIDINE AMIDE DERIVATIVE; BENZAMIDE DERIVATIVE; CHEMICAL COMPOUND; DIHYDROISOQUINOLINE DERIVATIVE; DIHYDRONAPHTHYRIDINONE DERIVATIVE; DIHYDROTHIAZOLOPYRIDONE DERIVATIVE; G PROTEIN COUPLED RECEPTOR; IMIDAZOPYRIMIDINONE DERIVATIVE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; MOLECULAR SCAFFOLD; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINAMIDE DERIVATIVE; PHTHALIMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; POSITIVE ALLOSTERIC MODULATOR; RADIOLIGAND; SULFONAMIDE; TETRAHYDROTHIAZOLOPYRIDINE DERIVATIVE; TETRAHYDROTRIAZOLOPYRIDINE; UNCLASSIFIED DRUG; LIGAND; MOLECULAR LIBRARY; NEW DRUG; PSYCHOTROPIC AGENT;

ALKYLATION; ALLOSTERISM; ARTICLE; BINDING SITE; BIOLOGICAL ACTIVITY; CHEMICAL BOND; CHEMICAL MODIFICATION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; EC50; EXPERIMENTAL HYPERACTIVITY; HIGH THROUGHPUT SCREENING; HUMAN; IC50; LIGAND BINDING; NONHUMAN; POLARIZATION; RECEPTOR AFFINITY; RECEPTOR BINDING ASSAY; SCHIZOPHRENIA; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TOXICITY; AGONISTS; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PROTEIN TERTIARY STRUCTURE; SYNTHESIS;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; HUMANS; LIGANDS; PROTEIN STRUCTURE, TERTIARY; PSYCHOTROPIC DRUGS; RECEPTOR, METABOTROPIC GLUTAMATE 5; SCHIZOPHRENIA; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84925940573     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666140826120419     Document Type: Article

References (131)

1. Kew, J.N. C.; Kemp, J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology, 2005, 179, 4-29.
2. Monn, J.A.; Johnson, M.P.; Schoepp, D.D. In: Handbook of Contemporary Neuropharmacology; Sibley, D.R.; Hanin, I.; Kuhar, M.; Skolnick, P., Ed.; Wiley-Interscience: New York, 2007; Vol. 1, pp. 421-464.
3. Lesage, A.S. J. Role of group I metabotropic glutamate receptors mGlu1 and mGlu5 in nociceptive signaling. Curr. Neuropharmacology, 2004, 2, 363-393.
4. Swanson, C.J. Bures, M.; Johnson, M.P.; Linden, A. -M.; Monn, J.A.; Schoepp, D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nature Rev. Drug Discov., 2005, 4, 131-144.
5. Chaki, S.; Yukio, A.; Palucha-Paniewiera, A.; Matrisciano, F.; Pilc, A. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology, 2013, 66, 40-52.
6. Um, J.W.; Kaufman, A.C.; Kostylev, M.; Heiss, J.K.; Stagi, M.; Takahashi, H.; Kerrisk, M.E.; Vortmeyer, A.; Wisniewski, T.; Koleske, A.J. Gunther, E.C.; Nygaard, H.B.; Strittmatter, S.M. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer A_ oligomer bound to cellular prion protein. Neuron, 2013, 79, 887-902.
7. Caraci, F.; Battaglia, G.; Sortino, M.A.; Spampinato, S.; Molinaro, G.; Copani, A.; Nicoletti, F.; Burno, V. Metabotropic glutamate receptors in neurodegeneration/neuroprotection: still a hot topic? Neurochem. Int., 2012, 61, 559-565.
8. Olive, M.F. Cognitive effects of group I metabotropic glutamate receptor ligands in the context of drug addiction. Eur. J. Pharmacol., 2010, 639, 47-58.
9. Doria, J.G.; Silva, F.R.; de Souza, J.M.; Vieira, L.B.; Carvalho, T.G.; Reis, H.J. Pereira, G.S.; Dobransky, T.; Ribeiro, F.M. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington_s disease. Br. J. Pharmacol., 2013, 169, 909-921.
10. Vinson, P.N.; Conn, P. J. Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Neuropharmacology, 2012, 62, 1461-1472.
11. Carlson, G.C. Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders. Pharmacol., Biochem. Behav., 2012, 100, 850-854.
12. Rosenbrock, H.; Kramer, G.; Hobson, S.; Koros, E.; Grundl, M.; Grauert, M.; Reymann, K.G.; Schröder, U.H. Functional interaction of metabotropic glutamate receptor 5 and NMDA-receptor by a metabotropic glutamate receptor 5 positive allosteric modulator. Eur. J. Pharmacol., 2010, 639, 40-46.
13. Perroy, J.; Raynaud, E.; Homburger, V.; Rousset, M. -C.; Telley, L.; Bockaert, J.; Fagni, L. J. Direct interaction enables cross-talk between ionotropic and group I metabotropic glutamate receptors. J. Biol. Chem., 2008, 283, 6799-6805.
14. Moghaddam, B.; Javitt, D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology, 2012, 37, 4-15.
15. Bleich, S.; Kornhuber, J. In: Dopamine and Glutamate in Psychiatric Disorders; Schmidt, W.J. Reith, M.E. A., Ed.; Humana Press, 2005, pp. 169-179.
16. Davis, B.M.; Beech, H.R. The effect of 1-arylcyclohexylamine (Sernyl) on twelve normal volunteers. J. Ment. Sci., 1960, 106, 912-924.
17. Pomarol-Clotet, E.; Honey, G.D.; Murray, G.K.; Corlett, P.R.; Absalom, A.R.; Lee, M.; McKenna, P.J. Bullmore, E.T.; Fletcher, P.C. Psychological effects of ketamine in healthy volunteers. Phenomenological study. Br. J. Psychiatry, 2006, 189, 173-179.
18. Luby, E.D.; Cohen, B.D. Rosenbaum, G.; Gottlieb, J.S.; Kelley, R. Study of a new schizophrenomimetic drug-Sernyl. Arch. Gen. Psychiatry, 1959, 81, 363-369.
19. Lahti, A.C.; Koffel, B.; LaPorte, D.; Tamminga, C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology, 1995, 13, 9-19.
20. F. Hoffmann-La Roche Ltd, http://www.roche.com/med-cor-2010-12-06b-e.pdf (Accessed May 15, 2014)
21. Awad, H.; Hubert, G.W.; Smith, Y.; Levey, A.I.; Conn, P. J. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci., 2000, 20, 7871-7879.
22. Awad, H.; Hubert, G.W.; Smith, Y.; Levey, A.I.; Conn, P. J. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci., 2000, 20, 7871-7879.
23. Mannaioni, G.; Marino, M.J. Valenti, O.; Traynelis, S.F.; Conn, P. J. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J. Neurosci., 2001, 21, 5925-5934.
24. Kunishima, N.; Shimada, Y.; Tsuji, Y.; Sato, T.; Yamamoto, M.; Kumasaka, T.; Nakanishi, S.; Jingami, H.; Morikawa, K. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature, 2000, 407, 971-977.
25. Tsuchiya, D.; Kunishima, N.; Kamiya, N.; Jingami, H.; Morikawa, K. Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd3+. Proc. Nat. Acad. Sci. U. S. A., 2002, 99, 2660-2665.
26. Muto, T.; Tsuchiya, D.; Morikawa, K.; Jingami, H. Structures of the extracellular regions of the group II/III metabotropic glutamate receptors. Proc. Nat. Acad. Sci. U. S. A., 2007, 104, 3759-3764.
27. Monn, J.A.; Massey, S. M.; Valli, M.J.; Henry, S.S.; Stephenson, G.A.; Bures, M.; Hérin, M.; Catlow, J.; Giera, D.; Wright, R.A.; Johnson, B.G.; Andis, S.L.; Kingston, A.; Schoepp, D.D. Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3. 1. 0]hexane-4, 6-dicarboxylate: identification of potent, selective and orally bioavailable agonists for mGlu2/3 receptors. J. Med. Chem., 2007, 50, 233-240.
28. Kingston, A.E.; Ornstein, P.L.; Wright, R.A.; Johnson, B.G.; Mayne, N.G.; Burnett, J.P.; Belagaje, R.; Wu, S.; Schoepp, D.D. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology, 1998, 37, 1-12.
29. Monn, J.A.; Prieto, L.; Taboada Martinez, L. Montero Salgado, C.; Shaw, B.W. MGlu2 agonists. PCT WO2011/084437 A1, July 14, 2011.
30. Prieto, L.; Walton, T.; Man, H.; Rudyk, H.; Clark, B.; Beadle, C.; Tupper, D.; Baker, S.; Hao, J.; Reinhard, M.; Henry, S.; Massey, S.; Taboada, L.; Lamas, C.; Dominguez, C.; Montero, C.; Marcos, A.; Blanco, J.; Atwell, S.; Thompson, D.; Emtage, S.; Lu, F; Swanson, S.; Bedwell, D.; McKinzie, D.; Pak, A.; Synthesis of LY2812223, a novel group II mGlu receptor agonist, and identification of LY 2979165, an effective oral prodrug. 7th International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, October 2-7, 2011.
31. Conn, P.J. Christopoulos, A.; Lindsley, C.W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature Rev. Drug Discovery, 2009, 8, 41-54.
32. Doherty, A.J. Palmer, M.J. Henley, J.M.; Collingridge, G.L.; Jane, D.E. (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and poten tiates NMDA responses in the hippocampus. Neuropharmacology, 1997, 36, 265-267.
33. o'Brien, J.A.; Lemaire, W.; Chen, T. -B.; Chang, R.S. L.; Jacobsen, M.A.; Ha, S.N.; Lindsley, C.W.; Schaffhauser, H.J. Sur, C.; Pettibone, D.J. Conn, P.J. Williams, JR.D. L. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol. Pharmacol. 2003, 54, 731-740.
34. Williams, Jr.D. L.; Lindsley, C.W. Discovery of positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5). Curr. Top. Med. Chem. 2005, 5, 825-846.
35. o'Brien, J.A.; Lemaire, W.; Wittman, M.; Jacobson, M.A.; Ha, S.N.; Wisnoski, D.D.; Lindsley, C.W.; Schaffhauser, H.J. Rowe, B.; Sur, C.; Duggan, M.E.; Pettibone, D.J. Conn, P.J. Williams, JR.D. L. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J. Pharmacol. Exp. Ther., 2004, 309, 568-577.
36. Zhao, Z.; Wisnoski, D.D.; o'Brien, J.A.; Lemaire, W.; Williams, JR.D. L.; Jacobson, M.A.; Wittman, M.; Ha, S.N.; Schaffhauser, H.; Sur, C.; Pettibone, D.J. Duggan, M.E.; Conn, P.J. Hartman, G.D.; Lindsley, C.W. Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA. Bioorg. Med. Chem. Lett., 2007, 17, 1386-1391.
37. Lindsley, C.W.; Wisnoski, D.D.; Leister, W.H.; o'Brien, J.A.; Lemaire, W.; Williams, Jr. D. L.; Burno, M.; Sur, C.; Kinney, G.G.; Pettibone, D.J.; Tiller, P.R.; Smith, S.; Duggan, M.E.; Hartman, G.D.; Conn, P.J.; Huff, J.R. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1, 3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J. Med. Chem., 2004, 47, 5825-5828.
38. Kinney, G.G.; o'Brien, J.A.; Lemaire, W.; Burno, M.; Bickel, D.J. Clements, M.K.; Chen, T. -B.; Wisnoski, D.D.; Lindsley, C.W.; Tiller, P.R.; Smith, S.; Jacobson, M.A.; Sur, C.; Duggan, M.E.; Pettibone, D.J. Conn, P.J. Williams, Jr.D. L. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Ther., 2005, 313, 199-206.
39. de Paulis, T.; Hemstapat, K.; Chen, Y.; Zhang, Y.; Saleh, S.; Alagille, D.; Baldwin, R.M.; Tamagnan, G.D.; Conn, P. J. Substituent effects of N-(1, 3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. J. Med. Chem., 2006, 49, 3332-3344.
40. Zou, M. -F.; Cao, J.; Rodriguez, A.L.; Conn, P.J.; Newman, A.H. Design and synthesis of substituted N-(1, 3-diphenyl-1H-pyrazol-5-yl)benzamides as positive allosteric modulators of the metabotropic glutamate receptor subtype 5. Bioorg. Med. Chem. Lett., 2011, 21, 2650-2654.
41. Xiong, H.; Brugel, T.A.; Balestra, M.; Brown, D.G.; Brush, K.A.; Hightower, C.; Hinkley, L.; Hoesch, V.; Kang, J.; Koether, G.M.; McCauley, Jr. J. P.; McLaren, F.M.; Panko, L.M.; Simpson, T.R.; Smith, R.W.; Woods, J.M.; Brockel, B.; Chhajlani, V.; Gadient, R.A.; Spear, N.; Sygowski, L.A.; Zhang, M.; Arora, J.; Breysse, N.; Wilson, J.M.; Isaac, M.; Slassi, A.; King, M.M. 4-Aryl piperazine and piperidine amides as novel mGluR5 positive allosteric modulators. Bioorg. Med. Chem. Lett., 2010, 20, 7381-7384.
42. Spear, N.; Gadient, R.A.; Wilkins, D.E.; Do, M.; Smith, J.S.; Zeller, K.L.; Schroeder, P.; Zhang, M.; Arora, J.; Chhajlani, V. Preclinical profile of a novel metabotropic glutamate receptor 5 positiveallosteric modulator. Eur. J. Pharmacol. 2011, 659, 146-154.
43. Zhou, Y.; Manka, J.; Rodriguez, A.L.; Weaver, C.D.; Days, E.L.; Vinson, P.N.; Jadhav, S.; Hermann, E.J.; Jones, C.K.; Conn, P.J.; Lindsley, C.W.; Stauffer, S.R. Discovery of N-aryl piperazines as selective mGluR5 potentiators with improved In vivo utility. ACS Med. Chem. Lett., 2010, 1, 433-438.
44. Liu, F.; Grauer, S.; Kelley, C.; Navarra, R.; Graf, R.; Zhang, G.; Atkinson, P.J. Popiolek, M.; Wantuch, C.; Khawaja, X.; Smith, D.; Olsen, M.; Kouranova, E.; Lai, M.; Pruthi, E.; Pulicicchio, C.; Day, M.; Gilbert, A.; Pausch, M.H.; Brandon, N.J. Beyer, C.E.; Comery, T.A.; Logue, S.; Rosenzweig-Lipson, S.; Marquis, K.L. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1, 2, 4]-oxadiazol-5-yl]-piperidin-1-yl}-ethanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J. Pharmacol. Exp. Ther., 2008, 327, 827-839.
45. Engers, D.W.; Rodriguez, A.L.; Williams, R.; Hammond, A.S.; Venable, D.; Oluwatola, O.; Sulikowski, G.A.; Conn, P.J. Lindsley, C.W. Synthesis, SAR and unanticipated pharmacological profiles of analogs of the mGluR5 ago-potentiator ADX-47273. ChemMedChem, 2009, 4, 505-511.
46. Lamb, J.P.; Engers, D.W.; Niswender, C.M.; Rodriguez, A.L.; Venable, D.F.; Conn, P.J. Lindsley, C.W. Discovery of molecular switches within the ADX-47273 mGlu5 PAM scaffold that modulate modes of pharmacology to afford potent mGlu5 NAMs, PAMs and partial antagonists. Bioorg. Med. Chem. Lett., 2011, 21, 2771-2714.
47. Packiarajan, M.; Mazza Ferreira, C.G.; Hong, S. -P.; White, A.D.; Chandrasena, G.; Pu, X.; Brodbeck, R.M.; Robichaud, A. J. N-Aryl pyrrolidinonyl oxadiazoles as potent mGluR5 positive allosteric modulators. Bioorg. Med. Chem. Lett., 2012, 22, 5658-5662.
48. Packiarajan, M.; Mazza Ferreira, C.G.; Hong, S. -P.; White, A.D.; Chandrasena, G.; Pu, X.; Brodbeck, R.M.; Robichaud, A. J. Azetidinyl oxadiazoles as potent mGluR5 positive allosteric modulators. Bioorg. Med. Chem. Lett., 2012, 22, 6469-6474.
49. Gilmour, G.; Broad, L.M.; Wafford, K.A.; Britton, T.; Colvin, E.M.; Fivush, A.; Gastambide, F.; Getman, B.; Heinz, B.A.; McCarthy, A.P.; Prieto, L.; Shanks, E.; Smith, J.W.; Taboada, L.; Edgar, D.M.; Tricklebank, M.D. in vitro characterisation of the novel positive allosteric modulators of the mGlu5 receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology, 2013, 64, 224-239.
50. Gastambide, F.; Gilmour, G.; Robbins, T.W.; Tricklebank, M.D. the mGlu5 positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat. Neuropharmacology, 2013, 64, 240-247.
51. Gastambide, F.; Cotel, M. -C.; Gilmour, G.; o'Neill, M.J. Robbins, T.W.; Tricklebank, M.D. selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator. Neuropsychopharmacology, 2012, 37, 1057-1066.
52. Vanejevs, M.; Jatzke, C.; Renner, S.; Müller, S.; Hechenberger, M.; Bauer, T.; Klochkova, A.; Pyatkin, I.; Kazyulkin, D.; Aksenova, E.; Shulepin, S.; Timonina, O.; Haasis, A.; Gutcaits, A.; Parsons, C.G.; Kauss, V.; Weil, T. Positive and negative modulation of group I metabotropic glutamate receptors. J. Med. Chem., 2008, 51, 634-647.
53. Sharma, S.; Rodriguez, A.L.; Conn, P.J. Lindsley, C.W. Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold. Bioorg. Med. Chem. Lett., 2008, 18, 4098-4101.
54. Sharma, S.; Kedrowski, J.; Rook, J.M.; Smith, R.L.; Jones, C.K.; Rodriguez, A.L.; Conn, P.J.; Lindsley, C.W. Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2-and 5-(phenylethynyl)pyrimidines. J. Med. Chem., 2009, 52, 4103-4106.
55. Ritzén, A.; Sindet, R.; Hentzer, M.; Svendsen, N.; Brodbeck, R.M.; Bundgaard, C. Disovery of a potent and brain penetrant mGluR5 positive allosteric modulator. Bioorg. Med. Chem. Lett., 2009, 19, 3275-3278.
56. Sams, A.G.; Mikkelsen, G.K.; Brodbeck, R.M.; Pu, X.; Ritzén A. Efficacy switching SAR of mGluR5 allosteric modulators: Highly potent positive and negative modulators from one chemotype. Bioorg. Med. Chem. Lett., 2011, 21, 3407-3410.
57. Rodriguez, A.L.; Grier, M.D.; Jones, C.K.; Herman, E.J. Kane, A.S.; Smith, R.L.; Williams, R.; Zhou, Y.; Marlo, J.E.; Days, E.M.; Blatt, T.N.; Jadhav, S.; Menon, U.N.; Vinson, P.N.; Rook, J.M.; Stauffer, S.R.; Niswender, C.M.; Lindsley, C.W.; Weaver, C.D.; Conn, P. J. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol. Pharmacol., 2010, 78, 1105-1123.
58. Williams, R.; Manka, J.T.; Rodriguez, A.L.; Vinson, P.N.; Niswender, C.M.; Weaver, C.D.; Jones, C.K.; Conn, P.J. Lindsley, C.W.; Stauffer, S.R. Synthesis and SAR of centrally active mGlu5 positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffold. Bioorg. Med. Chem. Lett., 2011, 21, 1350-1353.
59. Packiarajan, M.; Grenon, M.; Zorn, S.; Hopper, A.T.; White, A.D.; Chandrasena, G.; Pu, X.; Brodbeck, R.M.; Robichaud, A. J. Fused thiazolyl alkynes as potent mGlu5 receptor positive allosteric modulators. Bioorg. Med. Chem. Lett., 2013, 23, 4037-4043.
60. Varnes, J.G.; Marcus, A.P.; Mauger, R.C.; Throner, S.R.; Hoesch, V.; King, M.M.; Wang, X.; Sygowski, L.A.; Spear, N.; Gadient, R.; Brown, D.G.; Campbell, J.B. Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Bioorg. Med. Chem. Lett., 2011, 21, 1402-1406.
61. Hammond, A.S.; Rodriguez, A.L.; Townsend, S.D.; Niswender, C.M.; Gregory, K.J. Lindsley, C.W.; Conn, P. J. Discovery of a novel chemical class of mGlu5 allosteric ligands with distinct modes of pharmacology. ACS Chem. Neurosci., 2010, 1, 702-706.
62. Manka, J.T.; Vinson, P.N.; Gregory, K.J. Zhou, Y.; Williams, R.; Gogi, K.; Days, E.; Jadhav, S.; Herman, E.J. Lavreysen, H.; Mackie, C.; Bartolomé, J.M.; Macdonald, G.J. Steckler, T.; Daniels, J.S.; Weaver, C.D.; Niswender, C. M; Jones, C.K.; Conn, P.J. Lindsley, C.W. Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover. Bioorg. Med. Chem. Lett., 2012, 22, 6481-6185.
63. Bartolomé-Nebreda, J.M.; Conde-Ceide, S.; Delgado, F.; Iturrino, L.; Pastor, J.; Pena, M.A.; Trabanco, A.A.; Tresadern, G.; Wassvik, C.M.; Stauffer, S.R.; Jadhav, S.; Gogi, K.; Vinson, P.; Noetzel, M.; Days, E.; Weaver, C.D.; Lindsley, C.W.; Niswender, C.M.; Jone, C.K.; Conn, P.J.; Rombouts, F.; Lavreysen, H.; Macdonald, G.J.; Mackie, C.; Steckler, T. Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu) receptor. J. Med. Chem., 2013, 56, 7243-7259.
64. Rodriguez, A.L.; Zhou, Y.; Williams, R.; Weaver, C.D.; Vinson, P.N.; Dawson, E.S.; Steckler, T.; Lavreysen, H.; Mackie, C.; Bartolomé, J.M.; Macdonald, G.J. Daniels, J.S.; Niswender, C.M.; Jones, C.K.; Conn, P.J. Lindsley, C.W.; Stauffer, S.R. Discovery and SAR of a novel series of non-MPEP site mGlu5 PAMs based on an aryl glycine sulfonamide scaffold. Bioorg. Med. Chem. Lett., 2012, 22, 7388-7392.
65. Zhou, Y.; Rodriguez, A.L.; Williams, R.; Weaver, C.D.; Conn, J.P.; Lindsley, C.W. Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS. Bioorg. Med. Chem. Lett., 2009, 19, 6502-6506.
66. Horio, M.; Fujita Y.; Hashimoto, K. Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice. Fundamental & Clinical Pharmacol., 2013, 27, 483-488.
67. Lindsley, C.W.; Stauffer, S.R. Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004-2012). Pharmaceutical Patent Analyst, 2013, 2, 93-108.
68. Balschun, D.; Zuschratter, W.; Wetzel, W. Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory. Neuroscience, 2006, 142, 691-702.
69. Chan, M.H.; Chiu, P.H.; Sou, J.H.; Chen, H.H. Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice. Psychopharmacology, 2008, 198, 141-148.
70. Chen, Y.; Goudet, C.; Pin, J.P.; Conn, P. J. N-4-Chloro-2-[(1, 3-dioxo-1, 3-dihydro-2H-isoindol-2-yl)methyl]phenyl-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol. Pharmacol., 2008, 73, 909-918.
71. Noetzel, M.J. Gregory, K.J. Vinson, P.N.; Manka, J.T.; Stauffer, S.R.; Lindsley, C.W.; Niswender, C.M.; Xiang, Z.; Conn, P. J. A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Mol. Pharmacol., 2013, 83, 835-847.
72. Slassi, A.; Isaac, M.; Arora, J.; Brown, D.G. Piperazines and piperidines as mGluR5 potentiators. PCT WO2007/087135 A2, August 2, 2007.
73. Arora, J.; Isaac, M.; Slassi, A.; Edwards, L.; Nair, S.; Ma, F. Piperazine and piperidine mGluR5 potentiators. PCT WO2008/112440 A1, September 18, 2008.
74. Gianotti, M.; Lovell, P.J. Seri, C.; Tehan, B.G. Novel compounds. PCT WO2008/152089 A1, December 18, 2008.
75. Artioli, A.; Lovell, P. J. Novel compound. PCT WO2008/152090 A1, December 18, 2008.
76. Heimann, A.; Dahmann, G.; Grundl, M.; Mueller, S.G.; Wellenzohn, B. Piperazine derivatives and their use as positive allosteric modulators of mGlu5 receptors. PCT WO 2013/087805 A1, June 20, 2013.
77. Grauert, M.; Bischoff, D.; Dahmann, G.; Kuelzer, R.; Rudolf, K. Novel compounds. US patent 2013/0137688 A1, May 30, 2013.
78. Grauert, M.; Bischoff, D.; Dahmann, G.; Kuelzer, R.; Rudolf, K.; Wellenzohn, B. Novel compounds. US patent 2013/0143870 A1, June 6, 2013.
79. Grauert, M.; Bischoff, D.; Dahmann, G.; Kuelzer, R.; Rudolf, K. Novel compounds, US patent 2013/0184248 A1, July 18, 2013.
80. Grauert, M.; Bischoff, D.; Dahmann, G.; Kuelzer, R.; Rudolf, K.; Wellenzohn B. 1, 2, 4-triazoles as allosteric modulators of mGlu5 receptor activity for the treatment of schizophrenia or dementia. PCT WO 2013/083741 A1, June 13, 2013.
81. Rudolf, K.; Bischoff, D.; Dahmann, G.; Grauert, M.; Kuelzer, R. Piperazine derivatives and their use as positive allosteric modulators of mGlu5 receptors. PCT WO 2013/087806 A1, June 20, 2013.
82. Rudolf, K.; Bischoff, D.; Dahmann, G.; Grauert, M.; Kuelzer, R.; Wellenzohn, B. 4-Aryl imidazole derivatives as mGlu5 positive allosteric modulators. PCT WO 2013/087807 A1, June 20, 2013.
83. Rudolf, K.; Bischoff, D.; Dahmann, G.; Grauert, M.; Kuelzer, R. Novel compounds. US patent 2013/0150355 A1, June 13, 2013.
84. Rudolf, K.; Bischoff, D.; Dahmann, G.; Grauert, M.; Kuelzer, R.; Wellenzohn, B. Novel compounds. US patent 2013/0150347 A1, June 13, 2013.
85. Bessis, A. -S.; Bonnet, B.; Le Poul, E.; Rocher, J. -P.; Epping-Jordan, M. Allosteric modulators of metabotropic glutamate receptors. PCT WO 2005/044797 A1, May 19, 2005.
86. Bugada, P.; Gagliardi, S.; Le Poul, E.; Mutel, V.; Palombi, G.; Rocher, J. -P. Novel oxadiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors. PCT WO 2006/123249 A2, November 23, 2006.
87. Bugada, P.; Gagliardi, S.; Palombi, G.; Rocher, J. -P. Carbamate derivatives as positive allostericmodulators of metabotropic glutamate receptors. PCT WO 2006/123244 A2, November 23, 2006.
88. Farina, M.; Gagliardi, S.; Le Poul, E.; Mutel, V.; Palombi, G.; Poli, S.M.; Rocher, J. -P. Substitutedoxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors. PCT WO 2006/123255 A2, November 23, 2006.
89. Farina, M.; Gagliardi, S.; Le Poul, E.; Palombi, G; Rocher, J. -P. Novel heterocyclic compounds aspositive allosteric modulators of metabotropic glutamate receptors. PCT WO 2006/129199 A1, December 7, 2006.
90. Gagliardi, S.; Le Poul, E.; Lingard, L.; Palombi, G.; Poli, S.M.; Rocher, J. -P. Pyrrole derivatives aspositive allosteric modulators of metabotropic receptors. PCT WO 2006/123257 A2, November23, 2006.
91. Gagliardi, S.; Palombi, G.; Rocher, J. -P. Novel tetrazole derivatives as positive allostericmodulators of metabotropic glutamate receptors. PCT WO 2006/048771 A1, May 11, 2006.
92. Le Poul, E.; Palombi, G.; Rocher, J. -P. Oxazole derivatives as positive allosteric modulators ofmetabotropic glutamate receptors. PCT WO 2008/056259 A1, May 15, 2008.
93. Schlumberger, C.; Pietraszek, M.; Gravius, A.; Danysz, W. Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia. Pharmacol., Biochem. Behav. 2010, 95, 23-30.
94. Ayala, J.E.; Chen, Y.; Banko, J.L.; Sheffler, D.J. Williams, R.; Telk, A.N.; Watson, N.L.; Xiang, Z.; Zhang, Y.; Jones, P.J. Lindsley, C.W.; Olive, M.F.; Conn, P. J. mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology 2009, 34, 2057-2071.
95. Mercer, S.P.; Roecker, A.J. Williams, T.; Zhang, X. -F. 2-Alkyl piperidine mGluR5 receptormodulators. PCT WO 2010/124055 A1, October, 28, 2010.
96. Anthony, N.J. Gomez, R.P.; Li, J.; Mercer, S.P.; Roecker, A.J.; Stump, C.A.; Williams T.M. Tricyclic mGluR5 receptor modulators. PCT WO 2012/061019 A2, May 10, 2012.
97. Sisko, J.T.; Tucker, T.J. Tynebor, R.M. Caprolactam mGluR5 receptor modulators. PCT WO2012/058128 A2, May 3, 2012.
98. Parmentier-Batteur, S.; Hutson, P.H.; Menzel, K.; Uslaner, J.M.; Mattson, B.A.; OBrien, J.A.; Magliaro, B.C.; Forest, T.; Stump, C.A.; Tynebor, R.M.; Anthony, N.J. Tucker, T.J. Zhang, X. -F.; Gomez, R.; Huszar, S.L.; Lambeng, N.; Fauré, H.; Le Poul, E.; Rosahl, T.W.; Rocher, J. -P.; Hargreaves, R.; Williams, T.M. Mechanism based neurotoxicity of mGlu5 positive allostericmodulators _ development challenges for a promising novel antipsychotic target. Neuropharmacology, 2014, 82, 161-173.
99. Biemans, B.; Jaeschke, G.; Lindemann, L.; Muster, W.; Stadler, H.; Vieira, E. Pharmaceutically acceptable mGluR5 positive allosteric modulators and their methods of identification. PCTWO2013/ 045380 A2, April 4, 2013.
100. Prieto, L.; Taboada Martinez, L. Tetrahydrotriazolopyridine compounds as selective mGlu5receptor potentiators useful for the treatment of schizophrenia. PCT WO 2011/082010 A1, July 7, 2011.
101. Gasparini, F.; Lingenhöhl, K.; Stoehr, N.; Flor, P.J. Heinrich, M.; Vranesic, I.; Biollaz, M.; Allgeier, H.; Heckendorn, R.; Urwyler, S.; Varney, M.A.; Johnson, E.C.; Hess, S.D.; Rao, S.P.; Sacaan, A.I.; Santori, E.M.; Veliçelebi, G.; Kuhn, R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology, 1999, 38, 1493-1503.
102. Green, L.; Guba, W.; Jaeschke, G.; Jolidon, S.; Lindemann, L.; Ricci, A.; Rueher, D.; Stadler, H.; Vieira, E. Positive allosteric modulators. US patent 2011/0098313 A1, April 28, 2011.
103. Hopper, A; Sams, A.G.; Mikkelsen, G.K.; Packjarajan, M.; Grenon, M. 2-Substitutedethynylthiazole derivatives and uses of same. US patent 2011/0092475 A1, April 21, 2011.
104. Conn, P.J. Lindsley, C.W.; Weaver, C.D.; Rodriguez, A.L.; Niswender, C.M.; Jones, C.K.; Williams, R. Benzamide mGluR5 positive allosteric modulators and methods of making and using same. PCT WO 2008/151184 A1, December 11, 2008.
105. MacDonald, G.J. Tresadern, G.J. Trabanco-Suarez, A.A.; Pastor-Fernandez, J. Bicyclic thiazolesas allosteric modulators of mGluR5 receptors. PCT WO 2011/073347 A1, June 23, 2011.
106. Zemribo, R.; Fotins, J.; Abel, U.; Kubas, H.; Meyer, U.; Wolter, F.E.; Hechenberger, M. Dihydroindolizine derivate as metabotropic glutamate receptor modulators. PCT WO2012/172093 A1, December 20, 2012.
107. Jaeschke, G.; Lindemann, L.; Ricci, A.; Rueher, D.; Stadler, H.; Vieira, E. Ethynyl derivatives asmGluR5 allosteric modulators. PCT WO 2013/050454 A1, April 11, 2013.
108. Jaeschke, G.; Lindemann, L.; Ricci, A.; Rueher, D.; Stadler, H.; Vieira, E. Ethynyl derivatives asmetabotropic glutamate receptor modulators. PCT WO 2013/050460 A1, April 11, 2013.
109. Green, L.; Guba, W.; Jaeschke, G.; Jolidon, S.; Lindemann, L.; Ricci, A.; Rueher, D.; Stadler, H.; Vieira, E. Arylethynyl derivatives. US patent 2011/0251169 A1 October 13, 2011.
110. Jaeschke, G.; Jolidon, S.; Lindemann, L.; Stadler, H.; Vieira, E. Ethynyl derivatives as positiveallosteric modulators of the mGluR5. PCT WO 2012/146551 A1, November 1, 2012.
111. Jaeschke, G.; Jolidon, S.; Lindemann, L.; Ricci, A.; Rueher, D.; Stadler, H.; Vieira, E. Phenyl orpyridinyl-ethynyl derivatives. US patent 2012/0270852 A1, October 25, 2012.
112. Conn, P.J. Lindsley, C.W.; Stauffer, S. R; Zhou, Y.; Bartolome-Nebreda, J.M.; MacDonald, G.J. Gogliotti, R.D.; Turlington, M. Substituted 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mGluR5 receptors. PCT WO 2013/0490255 A1, April 4, 2013.
113. Hefferman, M.L. R.; Hardy, L.W.; Wu, F.X.; Saraswat, L.D. Metabotropic glutamate receptors 5 modulators and methods of use thereof. PCT WO 2012/162635 A1, November 29, 2012.
114. Degnan, A.P.; Huang, H.; Snyder, L.B.; Yang, F; Gillman, K.W.; Parker, M.F. Oxazolidinones as modulators of mGluR5. PCT WO 2012/064603 A1, May 18, 2012.
115. Green, L.; Guba, W.; Jaeschke, G.; Jolidon, S.; Lindemann, L.; Stadler, H.; Vieira, E. Ethynyl derivatives. PCT WO 2011/073172 A1, June 23, 2011.
116. Hendrich, M.; Weil, T.; Hechenberger, M.; Muller, S.; Kauss, V.; Zemribo, R.; Erdmane, E.; Smits, G. Metabotropic glutamate receptor modulators. PCT WO 2011/015343 A1, February 10, 2011.
117. Conn, P.J. Lindsley, C.W.; Stauffer, S.R.; Manka, J; Jacobs, J; Zhou, Y.S.; Bartolome-Nebreda, J.M.; MacDonald, G.; Conde-Ceide, S.; Jones, C.K. Naphthyridinone analogs as mGluR5 positive allosteric modulators. PCT WO 2012/092530 A1, July 5, 2012.
118. Conn, P.J. Lindsley, C.W.; Stauffer, S.R.; Manka, J; Jacobs, J; Zhou, Y.; Bartolome-Nebreda, J.M.; MacDonald, G.J; Conde-Ceide, S.; Dawson, E.S. Dihydronaphthyridinyl(organo)methanone analogs as positive allosteric mGLuR5 modulators. PCT WO 2012/097182 A1, July 19, 2012.
119. Conn, P.J.; Lindsley, C.W.; Stauffer, S.R.; Bartolome-Nebreda, J.M.; Conde-Ceide, S.; MacDonald, G.J.; Tong, H.M.; Jone, C.K.; Alcazar-Vaca, M.J.; Andres-Gil, J.I.; Malosh, C. Bicyclic triazole and pyrazole lactams as allosteric modulators of mGluR5 receptors. PCT WO 2012/083224 A1, June 21, 2012.
120. Conn, P.J. Lindsley, C.W.; Stauffer, S.R.; Jones, C.K.; Conde-Ceide, S.; Tong, H.M.; Bartolome-Nebreda, J.M.; MacDonald, G.J. Bicyclic pyrazole compounds as allosteric modulators of mGluR5 receptors. PCT WO 2012/078817 A1, June 14, 2012.
121. Conn, P.J. Lindsley, C.W.; Stauffer, S.R.; Bartolome-Nebreda, J.M.; MacDonald, G.J. Conde-Ceide, S.; Jones, C.K.; Martin-Martin, M.L.; Tong, H.M. Substituted imidazopyrididin-5(6H)-ones as allosteric modulators of mGluR5 receptors. PCT WO 2012/125732 A1, September 20, 2012.
122. Conn, P.J. Lindsley, C.W.; Stauffer, S.R.; Bartolome-Nebreda, J.M.; MacDonald, G.J. Conde-Ceide, S.; Martin-Martin, M.L. Bicyclic oxazole lactams as allosteric modulators of mGluR5 receptors. PCT WO 2013/130639 A1, September 6, 2013.
123. Conn, P.J. Lindsley, C.W.; Stauffer, S.R.; Jones, C.K.; Bartolome-Nebreda, J.M.; Conde-Ceide, S.; MacDonald, G.J.; Alcazar Vaca, M. J. Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors. PCT WO 2012/031024 A1, March 8, 2012.
124. Hefferman, M.L. R.; Hardy, L.W.; Wu, F.X.; Saraswat, L. D.; Spear, K.L. Metabotropic glutamate receptors 5 modulators and methods of use thereof. PCT WO2112/170845 A2, December 13, 2012.
125. Johnson, M.P.; Baez, M.; Jagdmann, Jr.G. E.; Britton, T.G.; Large, T.H.; Callagaro, D.O.; Tizzano, J.P.; Monn, J.A.; Schoepp, D.D. Discovery of Allosteric Potentiators for the Metabotropic Glutamate 2 Receptor: Synthesis and Subtype Selectivity of N-(4-(2-Methoxyphenoxy)phenyl)-N-(2, 2, 2_ trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J. Med. Chem., 2003, 46, 3189-3192.
126. Jimenez, H.N.; Li, G.; Doller, D.; Grenon, M.; White, A.D.; Guo, M.; Ma, G. Adamantyl diamide derivatives and use of same. PCT WO2010/011570 A1, January 28, 2010.
127. Rodriguez, A.L.; Williams, R.; Zhou, Y.; Lindsley, S.R.; Le, U.; Grier, M.D.; Weaver, C.D.; Conn, P.J. Lindsley, C.W. Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype. Bioorg. Med. Chem. Lett., 2009, 19, 3209-3213.
128. Noetzel, M.J. Rook, J.M.; Vinson, P.N.; Cho, H.P.; Days, E.; Zhou, Y.; Rodriguez, A.L.; Lavreysen, H.; Stauffer, S.R.; Niswender, C.M.; Xiang, Z.; Daniels, J.S.; Jones, C.K.; Lindsley, C.W.; Weaver, D.; Conn, P. J. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating center nervous system function. Mol. Pharmacol., 2012, 81, 120-133.
129. Rook, J.M.; Noetzel, M.J. Pouliot, W.A.; Bridges, T.M.; Vinson, P.N.; Cho, H.P.; Zhou, Y.; Gogliotti, R.D.; Manka, J.T.; Gregory, K.J. Stauffer, S.R.; Dudek, F.E.; Xiang, Z.; Niswender, C.M.; Daniels, J.S.; Jones, C.K.; Lindsley, C.W.; Conn, P. J. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity. Biol. Psychiatry, 2013, 73, 501-509.
130. Bradley, S.J. Langmead, C.J. Watson, J.M.; Challiss, R.A. J. Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astrogilia. Mol. Pharmacol., 2011, 79, 874-885.
131. Bird, M.K.; Lawrence, A. J. The promiscuous mGlu5 receptor _ a range of partners for the therapeutic possibilities? Trends Pharmacol. Sci., 2009, 30, 617-623